Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus ankara vaccines in neonate rhesus macaques

Journal of Virology

Volumn 84, Issue 15, 2010, Pages 7815-7821

  Rosario, Maximillian ^a   Fulkerson, John ^b   Soneji, Shamit ^a   Parker, Joe ^a   Im, Eung Jun ^a,d   Borthwick, Nicola ^a   Bridgeman, Anne ^a   Bourne, Charles ^b   Joseph, Joan ^c   Sadoff, Jerald C ^b   Hanke, Tomáš ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Aeras Global TB Vaccine Foundation   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE;

ANIMAL EXPERIMENT; ARTICLE; DRUG RESPONSE; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION;

AIDS VACCINES; ANIMALS; ANIMALS, NEWBORN; BCG VACCINE; GENETIC VECTORS; HIV-1; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; LYMPHOCYTES; MACACA MULATTA; MYCOBACTERIUM BOVIS; VACCINES, SYNTHETIC; VACCINIA VIRUS;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; MYCOBACTERIUM BOVIS BCG; VACCINIA VIRUS ANKARA;

EID: 77954491966     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00726-10     Document Type: Article

References (48)

1. Adkins, B., C. Leclerc, and S. Marshall-Clarke. 2004. Neonatal adaptive immunity comes of age. Nat. Rev. Immunol. 4:553-564.
2. Barnhart, H. X., M. B. Caldwell, P. Thomas, L. Mascola, I. Ortiz, H. W. Hsu, J. Schulte, R. Parrott, Y. Maldonado, and R. Byers. 1996. Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project. Pediatrics 97:710-716.
3. Cayabyab, M. J., B. Korioth-Schmitz, Y. Sun, A. Carville, H. Balachandran, A. Miura, K. R. Carlson, A. P. Buzby, B. F. Haynes, W. R. Jacobs, and N. L. Letvin. 2009. Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses. J. Virol. 83:5505-5513.
4. Coovadia, H. M., N. C. Rollins, R. M. Bland, K. Little, A. Coutsoudis, M. L. Bennish, and M. L. Newell. 2007. Mother-to-child transmission of HIV-1 infection during exclusive breast-feeding in the first 6 months of life: an intervention cohort study. Lancet 369:1107-1116.
5. + T lymphocytes into Th1/Th2 effectors. Vaccine 16:1415-1419.
6. Dunn, D. T., M. L. Newell, A. E. Ades, and C. S. Peckham. 1992. Risk of human immunodeficiency virus type 1 transmission through breast-feeding. Lancet 340:585-588.
7. Edelman, R., K. Palmer, K. G. Russ, H. P. Secrest, J. A. Becker, S. A. Bodison, J. G. Perry, A. R. Sills, A. G. Barbour, C. J. Luke, M. S. Hanson, C. K. Stover, J. E. Burlein, G. P. Bansal, E. M. Connor, and S. Koenig. 1999. Safety and immunogenicity of recombinant bacille Calmette-Guerin (rBCG) expressing Borrelia burgdorferi outer-surface protein A (OspA) lipopotein in adults volunteers: a candidate Lyme disease vaccine. Vaccine 17:904-919.
8. Goriely, S., B. Vincart, P. Stordeur, J. Vekemans, F. Willems, M. Goldman, and D. De Wit. 2001. Deficient IL-12(p35) gene expression by dendritic cells derived from neonatal monocytes. J. Immunol. 166:2141-2146.
9. Goulder, P. J., P. Jeena, G. Tudor-Williams, and S. Burchett. 2001. Paediatric HIV infection: correlates of protective immunity and global perspectives in prevention and management. Br. Med. Bull. 58:89-108.
10. Goulder, P. J., C. Pasquier, E. C. Holmes, B. Liang, Y. Tang, J. Izopet, K. Saune, E. S. Rosenberg, S. K. Burchett, K. McIntosh, M. Barnardo, M. Bunce, B. D. Walker, C. Brander, and R. E. Phillips. 2001. Mother-tochild transmission of HIV infection and CTL escape through HLA-A2-SLYNTVATL epitope sequence variation. Immunol. Lett. 79:109-116.
11. Grode, L., P. Seiler, S. Baumann, J. Hess, V. Brinkmann, A. Nasser Eddine, P. Mann, C. Goosmann, S. Bandermann, D. Smith, G. J. Bancroft, J. M. Reyrat, D. van Soolingen, B. Raupach, and S. H. Kaufmann. 2005. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J. Clin. Invest. 115:2472-2479.
12. Hanke, T. 2008. STEP trial and HIV-1 vaccines inducing T-cell responses. Expert Rev. Vaccines 7:303-309.
13. Hanke, T., N. Goonetilleke, A. J. McMichael, and L. Dorrell. 2007. Clinical experience with plasmid DNA- and modified vaccinia vaccine Ankara (MVA)-vectored HIV-1 clade A vaccine inducing T cells. J. Gen. Virol. 88:1-12.
14. Hanke, T., and A. J. McMichael. 2000. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat. Med. 6:951-955.
15. Hess, J., D. Miko, A. Catic, V. Lehmensiek, D. G. Russell, and S. H. Kaufmann. 1998. Mycobacterium bovis Bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc. Natl. Acad. Sci. U. S. A. 95: 5299-5304.
16. Hussey, G. D., M. L. Watkins, E. A. Goddard, S. Gottschalk, E. J. Hughes, K. Iloni, M. A. Kibel, and S. R. Ress. 2002. Neonatal mycobacterial specific cytotoxic T-lymphocyte and cytokine profiles in response to distinct BCG vaccination strategies. Immunology 105:314-324.
17. + T cells by a 4-component DNA-MVA/ HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques. Eur. J. Immunol. 36:2574-2584.
18. Im, E. J., N. Saubi, G. Virgili, C. Sander, D. Teoh, J. M. Gatell, H. McShane, J. Joseph, and T. Hanke. 2007. Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breast-feeding. J. Virol. 81:9408-9418.
19. Joseph, J., N. Saubi, E. Pezzat, and J. M. Gatell. 2006. Progress toward an HIV vaccine based on recombinant bacillus Calmette-Guerin: failures and challenges. Expert Rev. Vaccines 5:827-838.
20. Kagina, B. M., B. Abel, M. Bowmaker, T. J. Scriba, S. Gelderbloem, E. Smit, M. Erasmus, N. Nene, G. Walzl, G. Black, G. D. Hussey, A. C. Hesseling, and W. A. Hanekom. 2009. Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T-cell response. Vaccine 27: 5488-5495.
21. Katamura, K., Y. Tabata, Y. Oshima, N. Shintaku, Y. Yamauchi, and M. Mayumi. 1995. Selective induction of interleukin-4- and interferon-γ- producing T cells from cord blood naive T cells: effects of costimulatory signaling through CD28. Int. Arch. Allergy Immunol. 106:101-106.
22. Kuhn, L., G. M. Aldrovandi, M. Sinkala, C. Kankasa, K. Semrau, M. Mwiya, P. Kasonde, N. Scott, C. Vwalika, J. Walter, M. Bulterys, W. Y. Tsai, and D. M. Thea. 2008. Effects of early, abrupt weaning on HIV-free survival of children in Zambia. N. Engl. J. Med. 359:130-141.
23. Kuhn, L., Z. Stein, and M. Susser. 2004. Preventing mother-to-child HIV transmission in the new millennium: the challenge of breast feeding. Paediatr. Perinat. Epidemiol. 18:10-16.
24. Marchant, A., T. Goetghebuer, M. O. Ota, I. Wolfe, S. J. Ceesay, D. De Groote, T. Corrah, S. Bennett, J. Wheeler, K. Huygen, P. Aaby, K. P. McAdam, and M. J. Newport. 1999. Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guerin vaccination. J. Immunol. 163:2249-2255.
25. Marchant, A., and M. Goldman. 2005. T cell-mediated immune responses in human newborns: ready to learn? Clin. Exp. Immunol. 141:10-18.
26. Marchant, A., and M. Newport. 2000. Prevention of infectious diseases by neonatal and early infantile immunization: prospects for the new millennium. Curr. Opin. Infect. Dis. 13:241-246.
27. Marodi, L. 2006. Innate cellular immune responses in newborns. Clin. Immunol. 118:137-144.
28. Mbori-Ngacha, D., R. Nduati, G. John, M. Reilly, B. Richardson, A. Mwatha, J. Ndinya-Achola, J. Bwayo, and J. Kreiss. 2001. Morbidity and mortality in breast-fed and formula-fed infants of HIV-1-infected women: a randomized clinical trial. JAMA 286:2413-2420. (Pubitemid 33098159)
29. Miller, M. D., H. Yamamoto, A. L. Hughes, D. I. Watkins, and N. L. Letvin. 1991. Definition of an epitope and MHC class I molecule recognized by gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys. J. Immunol. 147:320-329.
30. Milush, J. M., D. Kosub, M. Marthas, K. Schmidt, F. Scott, A. Wozniakowski, C. Brown, S. Westmoreland, and D. L. Sodora. 2004. Rapid dissemination of SIV following oral inoculation. AIDS 18:2371-2380.
31. Mwau, M., I. Cebere, J. Sutton, P. Chikoti, N. Winstone, E. G.-T. Wee, T. Beattie, Y.-H. Chen, L. Dorrel, H. McShane, C. Schmidt, M. Brooks, S. Patel, J. Roberts, C. Conlon, S. Rowland-Jones, J. Bwayo, A. J. McMichael, and T. Hanke. 2004. An HIV-1 clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol. 85:911-919.
32. Mwau, M., A. J. McMichael, and T. Hanke. 2002. Design and validation of an ELISPOT assay for use in clinical trials of candidate HIV vaccines. AIDS Res. Hum. Retrovir. 18:611-618.
33. Nkolola, J. P., E. G.-T. Wee, E.-J. Im, C. P. Jewell, N. Chen, X.-N. Xu, A. J. McMichael, and T. Hanke. 2004. Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa. Gene Ther. 11:1068-1080.
34. Ota, M. O., J. Vekemans, S. E. Schlegel-Haueter, K. Fielding, M. Sanneh, M. Kidd, M. J. Newport, P. Aaby, H. Whittle, P. H. Lambert, K. P. McAdam, C. A. Siegrist, and A. Marchant. 2002. Influence of Mycobacterium bovis bacillus Calmette-Guerin on antibody and cytokine responses to human neonatal vaccination. J. Immunol. 168:919-925.
35. Pirenne-Ansart, H., F. Paillard, D. De Groote, A. Eljaafari, S. Le Gac, P. Blot, P. Franchimont, C. Vaquero, and G. Sterkers. 1995. Defective cytokine expression but adult-type T-cell receptor, CD8, and p56lck modulation in CD3- or CD2-activated T cells from neonates. Pediatr. Res. 37:64-69.
36. Rosario, M., R. Hopkins, J. Fulkerson, N. Bortwick, M. F. Quigley, J. Joseph, D. C. Douek, H. Y. Greenaway, V. Venturi, E. Gostick, D. A. Price, G. W. Both, J. C. Sadoff, and T. Hanke. 2010. Novel recombinant BCG, ovine atadenovirus and modified vaccinia virus Ankara vaccines combine to induce robust polyfunctional human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques. J. Virol. 84:5898-5908.
37. Siegrist, C. A. 2001. Neonatal and early life vaccinology. Vaccine 19:3331-3346.
38. Soares, A. P., T. J. Scriba, S. Joseph, R. Harbacheuski, R. A. Murray, S. J. Gelderbloem, A. Hawkridge, G. D. Hussey, H. Maecker, G. Kaplan, and W. A. Hanekom. 2008. Bacillus Calmette-Guerin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J. Immunol. 180:3569-3577.
39. Someya, K., D. Cecilia, Y. Ami, T. Nakasone, K. Matsuo, S. Burda, H. Yamamoto, N. Yoshino, M. Kaizu, S. Ando, K. Okuda, S. Zolla-Pazner, S. Yamazaki, N. Yamamoto, and M. Honda. 2005. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guerin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif. J. Virol. 79:1452-1462.
40. Sun, R., Y. A. Skeiky, A. Izzo, V. Dheenadhayalan, Z. Imam, E. Penn, K. Stagliano, S. Haddock, S. Mueller, J. Fulkerson, C. Scanga, A. Grover, S. C. Derrick, S. Morris, D. M. Hone, M. A. Horwitz, S. H. Kaufmann, and J. C. Sadoff. 2009. Novel recombinant BCG expressing perfringolysin O and the overexpression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 27:4412-4423.
41. Van Rompay, K. K., K. Abel, J. R. Lawson, R. P. Singh, K. A. Schmidt, T. Evans, P. Earl, D. Harvey, G. Franchini, J. Tartaglia, D. Montefiori, S. Hattangadi, B. Moss, and M. L. Marthas. 2005. Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J. Acquir. Immune Defic. Syndr. 38:124-134.
42. Van Rompay, K. K., J. L. Greenier, K. S. Cole, P. Earl, B. Moss, J. D. Steckbeck, B. Pahar, T. Rourke, R. C. Montelaro, D. R. Canfield, R. P. Tarara, C. Miller, M. B. McChesney, and M. L. Marthas. 2003. Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J. Virol. 77:179-190.
43. + T lymphocytes. Eur. J. Immunol. 31:1531-1535.
44. Vekemans, J., M. O. Ota, E. C. Wang, M. Kidd, L. K. Borysiewicz, H. Whittle, K. P. McAdam, G. Morgan, and A. Marchant. 2002. T-cell responses to vaccines in infants: defective IFNγ production after oral polio vaccination. Clin. Exp. Immunol. 127:495-498.
45. Wee, E. G.-T., S. Patel, A. J. McMichael, and T. Hanke. 2002. A DNA/MVAbased candidate HIV vaccine for Kenya induces multi-specific T-cell responses in rhesus macaques. J. Gen. Virol. 83:75-80.
46. Wu, C. Y., C. Demeure, M. Kiniwa, M. Gately, and G. Delespesse. 1993. IL-12 induces the production of IFN-gamma by neonatal human CD4 T cells. J. Immunol. 151:1938-1949.
47. Yasutomi, Y., S. Koenig, S. S. Haun, C. K. Stover, R. K. Jackson, P. Conard, A. J. Conley, E. A. Emini, T. R. Fuerst, and N. L. Letvin. 1993. Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys. J. Immunol. 150:3101-3107. (Pubitemid 23127560)
48. Yu, J. S., J. W. Peacock, S. Vanleeuwen, T. Hsu, W. R. Jacobs, Jr., M. J. Cayabyab, N. L. Letvin, R. Frothingham, H. F. Staats, H. X. Liao, and B. F. Haynes. 2006. Generation of mucosal anti-human immunodeficiency virus type 1 T-cell responses by recombinant Mycobacterium smegmatis. Clin. Vaccine Immunol. 13:1204-1211.